USPlabs Crafts DMAA Defense As Shield Against Further Damage
This article was originally published in The Tan Sheet
Executive Summary
USPlabs’ compliance with FDA’s request to cease marketing DMAA-containing products came following lengthy and detailed responses to the agency that could shield the firm from class action lawsuits and state investigations.